The Food and Drug Administration (news - web sites) is revamping how it reviews drugs to treat, diagnose and prevent cancer, hoping to speed evaluation of the products. Under the restructuring, a new Office of Oncology Drug Products will oversee both traditional chemotherapies and biologically based treatments, as well as imaging agents to diagnose cancer and the new field of cancer prevention drugs. The hope is that having everything under one roof not only could speed evaluation, but ensure they’re all held to the same scientific standards.
